This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectrum Pharmaceuticals Announces Promotion Of Joseph Turgeon To Senior Vice President And Chief Commercial Officer As Company Builds On Recent Commercial Reorganization To Advance Growth And Market Penetration Over The Next Five Years

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer (CCO). Mr. Turgeon joined Spectrum in October 2012 as Senior Vice President Sales & Commercial Operations, bringing over 25 years of pharma sales experience, including various executive leadership roles at Amgen. In his new capacity as CCO, Mr. Turgeon will be responsible for global commercial and sales activities, reporting to Spectrum Pharmaceuticals’ Executive Vice President, Chief Operating Officer, Ken Keller. Currently, Spectrum markets three oncology products in the U.S. – FUSILEV® (levoleucovorin) for Injection; FOLOTYN® (pralatrexate injection); and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use – with ex-U.S. rights for ZEVALIN as well.

"As we reported in our presentation earlier this week at the Annual J.P. Morgan Healthcare Conference, Spectrum is committed to continued strong growth over the next five years, with three anticancer drugs on the market and nearly ten drugs in clinical development," said Dr. Shrotriya. "Mr. Turgeon, working closely with Ken Keller, Executive Vice President, Chief Operating Officer, already has contributed greatly to executing our planned strategy for expedited growth of the Company under our recent commercial reorganization, and we are pleased to announce his promotion to CCO and responsibilities for our global commercial presence."

"Every day at Spectrum, we see new opportunities and new ways to apply our knowledge to further accelerate our momentum and increase our footprint in the market. Each of our current products on the market has a unique set of benefits for patients and unique abilities to address current needs, as is true of our late-stage development product candidates. With our commercial reorganization and drive to succeed, Spectrum is in a stronger position than ever to communicate these advantages to physicians and patients," stated Mr. Turgeon.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs